

NCT ID	NCT03785249
Title	Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Phase	Phase 1
Date Added	2018-12-24
Location	Alabama, United States Alaska, United States Arizona, United States California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Puerto Rico
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	afatinib, cetuximab, MRTX849, Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06066424
Title	Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
Phase	Phase 1
Date Added	2023-10-04
Location	Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Cyclophosphamide, Fludarabine Phosphate, Rimiducid, TROP2-CAR-NK Cells
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	PG545 (pixatimod) in combination with nivolumab

Title	PG545 (pixatimod) in combination with nivolumab
Phase	Phase 1
Date Added	2019-04-26
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06841159
Title	Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) Combined With Anti-PD1?Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2025-03-25
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT05349890
Title	Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Phase	Phase 1
Date Added	2022-04-27
Location	Oregon, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	CDX-1140, Pembrolizumab, Keytruda
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT02600949
Title	Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Phase	Phase 1
Date Added	2015-11-09
Location	Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03568058
Title	Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
Phase	Phase 1
Date Added	2018-06-26
Location	California, United States
Prior IO Allowed	Yes
CRC-directed	No

Status	Active, not recruiting
Drugs	Pembrolizumab, personalized vaccine, Keytruda
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT04096417
Title	Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Phase	Phase 2
Date Added	2019-09-19
Location	Arizona, United States Georgia, United States Minnesota, United States North Carolina, United States Tennessee, United States Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pemigatinib
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT04014530
Title	Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
Phase	Phase 1
Date Added	2019-07-10
Location	Netherlands
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Ataluren + Pembrolizumab, Keytruda
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03519412
Title	Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Phase	Phase 2
Date Added	2018-05-09
Location	Italy
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	pembrolizumab (treatment), temozolomide (induction),, Keytruda, Temodar
Tags	MSS/ MMRp